Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

386 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Expression of mage genes by non-small-cell lung carcinomas.
Weynants P, Lethé B, Brasseur F, Marchand M, Boon T. Weynants P, et al. Among authors: marchand m. Int J Cancer. 1994 Mar 15;56(6):826-9. doi: 10.1002/ijc.2910560612. Int J Cancer. 1994. PMID: 8119772
Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA.
Liénard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, Batard P, Guillaume P, Ayyoub M, Pittet MJ, Zippelius A, Fleischhauer K, Lejeune F, Cerottini JC, Romero P, Speiser DE. Liénard D, et al. Among authors: marchand m. Cancer Immun. 2004 May 19;4:4. Cancer Immun. 2004. PMID: 15149168 Clinical Trial.
Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N, Bonnet MC, Dréno B, Khammari A, Dorval T, Piperno-Neumann S, Liénard D, Speiser D, Marchand M, Brichard VG, Escudier B, Négrier S, Dietrich PY, Maraninchi D, Osanto S, Meyer RG, Ritter G, Moingeon P, Tartaglia J, van der Bruggen P, Coulie PG, Boon T. van Baren N, et al. Among authors: marchand m. J Clin Oncol. 2005 Dec 10;23(35):9008-21. doi: 10.1200/JCO.2005.08.375. Epub 2005 Aug 1. J Clin Oncol. 2005. PMID: 16061912 Clinical Trial.
Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Kruit WH, et al. Among authors: marchand m. Int J Cancer. 2005 Nov 20;117(4):596-604. doi: 10.1002/ijc.21264. Int J Cancer. 2005. PMID: 15945101 Clinical Trial.
Immunologic analysis of a phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors.
Vantomme V, Dantinne C, Amrani N, Permanne P, Gheysen D, Bruck C, Stoter G, Britten CM, Keilholz U, Lamers CH, Marchand M, Delire M, Guéguen M. Vantomme V, et al. Among authors: marchand m. J Immunother. 2004 Mar-Apr;27(2):124-35. doi: 10.1097/00002371-200403000-00006. J Immunother. 2004. PMID: 14770084 Clinical Trial.
Peptide-based cancer vaccines.
Machiels JP, van Baren N, Marchand M. Machiels JP, et al. Among authors: marchand m. Semin Oncol. 2002 Oct;29(5):494-502. doi: 10.1053/sonc.2002.35244. Semin Oncol. 2002. PMID: 12407514 Review.
Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.
Coulie PG, Karanikas V, Lurquin C, Colau D, Connerotte T, Hanagiri T, Van Pel A, Lucas S, Godelaine D, Lonchay C, Marchand M, Van Baren N, Boon T. Coulie PG, et al. Among authors: marchand m. Immunol Rev. 2002 Oct;188:33-42. doi: 10.1034/j.1600-065x.2002.18804.x. Immunol Rev. 2002. PMID: 12445279 Review.
386 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page